English
简体中文
Total: £ 56.28
Published Date: 2025-10-15 | Pages: 144 | Tables: 144 | Medical Care
The global Bulk-Drug Compounding market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.
Bulk-drug compounding refers to the process of creating medications by combining, mixing, or altering ingredients to tailor a drug specifically for an individual patient's needs. This is typically done by licensed pharmacists or physicians when commercially available medications are unsuitable for a patient. It plays a crucial role in addressing specific medical conditions that require unique formulations or dosages.
From a downstream perspective, Prescription Drugs accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
Bulk-Drug Compounding leading manufacturers including Fogron, B.Broun Melsungen AG, Nephron Pharmaceuticals Corporaiton, Athenex Pharmaceutical Division, QuVa Pharma, Fresenius Kabi, Central Admixture Pharmacy Services Inc, PharMEDium, Avella Speciality Pharmacy, ImprimisRx, etc., dominate supply; the top five capture approximately % of global revenue, with Fogron leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).
Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Bulk-Drug Compounding market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Fogron
B.Broun Melsungen AG
Nephron Pharmaceuticals Corporaiton
Athenex Pharmaceutical Division
QuVa Pharma
Fresenius Kabi
Central Admixture Pharmacy Services Inc
PharMEDium
Avella Speciality Pharmacy
ImprimisRx
Edge Pharma
SCA Pharma
New England Compounding Center
Bellevue Pharmacy
Pharmazone
Segment by Type
Sterile Compounding
Non-sterile Compounding
Segment by Application
Prescription Drugs
Over-the-Counter Drugs
Sales by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the Bulk-Drug Compounding study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Study Coverage
1.1 Introduction to Bulk-Drug Compounding: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Bulk-Drug Compounding Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Sterile Compounding
1.2.3 Non-sterile Compounding
1.3 Market Segmentation by Application
1.3.1 Global Bulk-Drug Compounding Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Prescription Drugs
1.3.3 Over-the-Counter Drugs
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Bulk-Drug Compounding Revenue Estimates and Forecasts 2020-2031
2.2 Global Bulk-Drug Compounding Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Bulk-Drug Compounding Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Bulk-Drug Compounding Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Sterile Compounding Market Size by Players
3.3.2 Non-sterile Compounding Market Size by Players
3.4 Global Bulk-Drug Compounding Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Bulk-Drug Compounding Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Bulk-Drug Compounding Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Bulk-Drug Compounding Market Size by Type (2020-2031)
6.4 North America Bulk-Drug Compounding Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Bulk-Drug Compounding Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Bulk-Drug Compounding Market Size by Type (2020-2031)
7.4 Europe Bulk-Drug Compounding Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Bulk-Drug Compounding Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Bulk-Drug Compounding Market Size by Type (2020-2031)
8.4 Asia-Pacific Bulk-Drug Compounding Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Bulk-Drug Compounding Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Bulk-Drug Compounding Market Size by Type (2020-2031)
9.4 Central and South America Bulk-Drug Compounding Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Bulk-Drug Compounding Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Bulk-Drug Compounding Market Size by Type (2020-2031)
10.4 Middle East and Africa Bulk-Drug Compounding Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Bulk-Drug Compounding Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Fogron
11.1.1 Fogron Corporation Information
11.1.2 Fogron Business Overview
11.1.3 Fogron Bulk-Drug Compounding Product Features and Attributes
11.1.4 Fogron Bulk-Drug Compounding Revenue and Gross Margin (2020-2025)
11.1.5 Fogron Bulk-Drug Compounding Revenue by Product in 2024
11.1.6 Fogron Bulk-Drug Compounding Revenue by Application in 2024
11.1.7 Fogron Bulk-Drug Compounding Revenue by Geographic Area in 2024
11.1.8 Fogron Bulk-Drug Compounding SWOT Analysis
11.1.9 Fogron Recent Developments
11.2 B.Broun Melsungen AG
11.2.1 B.Broun Melsungen AG Corporation Information
11.2.2 B.Broun Melsungen AG Business Overview
11.2.3 B.Broun Melsungen AG Bulk-Drug Compounding Product Features and Attributes
11.2.4 B.Broun Melsungen AG Bulk-Drug Compounding Revenue and Gross Margin (2020-2025)
11.2.5 B.Broun Melsungen AG Bulk-Drug Compounding Revenue by Product in 2024
11.2.6 B.Broun Melsungen AG Bulk-Drug Compounding Revenue by Application in 2024
11.2.7 B.Broun Melsungen AG Bulk-Drug Compounding Revenue by Geographic Area in 2024
11.2.8 B.Broun Melsungen AG Bulk-Drug Compounding SWOT Analysis
11.2.9 B.Broun Melsungen AG Recent Developments
11.3 Nephron Pharmaceuticals Corporaiton
11.3.1 Nephron Pharmaceuticals Corporaiton Corporation Information
11.3.2 Nephron Pharmaceuticals Corporaiton Business Overview
11.3.3 Nephron Pharmaceuticals Corporaiton Bulk-Drug Compounding Product Features and Attributes
11.3.4 Nephron Pharmaceuticals Corporaiton Bulk-Drug Compounding Revenue and Gross Margin (2020-2025)
11.3.5 Nephron Pharmaceuticals Corporaiton Bulk-Drug Compounding Revenue by Product in 2024
11.3.6 Nephron Pharmaceuticals Corporaiton Bulk-Drug Compounding Revenue by Application in 2024
11.3.7 Nephron Pharmaceuticals Corporaiton Bulk-Drug Compounding Revenue by Geographic Area in 2024
11.3.8 Nephron Pharmaceuticals Corporaiton Bulk-Drug Compounding SWOT Analysis
11.3.9 Nephron Pharmaceuticals Corporaiton Recent Developments
11.4 Athenex Pharmaceutical Division
11.4.1 Athenex Pharmaceutical Division Corporation Information
11.4.2 Athenex Pharmaceutical Division Business Overview
11.4.3 Athenex Pharmaceutical Division Bulk-Drug Compounding Product Features and Attributes
11.4.4 Athenex Pharmaceutical Division Bulk-Drug Compounding Revenue and Gross Margin (2020-2025)
11.4.5 Athenex Pharmaceutical Division Bulk-Drug Compounding Revenue by Product in 2024
11.4.6 Athenex Pharmaceutical Division Bulk-Drug Compounding Revenue by Application in 2024
11.4.7 Athenex Pharmaceutical Division Bulk-Drug Compounding Revenue by Geographic Area in 2024
11.4.8 Athenex Pharmaceutical Division Bulk-Drug Compounding SWOT Analysis
11.4.9 Athenex Pharmaceutical Division Recent Developments
11.5 QuVa Pharma
11.5.1 QuVa Pharma Corporation Information
11.5.2 QuVa Pharma Business Overview
11.5.3 QuVa Pharma Bulk-Drug Compounding Product Features and Attributes
11.5.4 QuVa Pharma Bulk-Drug Compounding Revenue and Gross Margin (2020-2025)
11.5.5 QuVa Pharma Bulk-Drug Compounding Revenue by Product in 2024
11.5.6 QuVa Pharma Bulk-Drug Compounding Revenue by Application in 2024
11.5.7 QuVa Pharma Bulk-Drug Compounding Revenue by Geographic Area in 2024
11.5.8 QuVa Pharma Bulk-Drug Compounding SWOT Analysis
11.5.9 QuVa Pharma Recent Developments
11.6 Fresenius Kabi
11.6.1 Fresenius Kabi Corporation Information
11.6.2 Fresenius Kabi Business Overview
11.6.3 Fresenius Kabi Bulk-Drug Compounding Product Features and Attributes
11.6.4 Fresenius Kabi Bulk-Drug Compounding Revenue and Gross Margin (2020-2025)
11.6.5 Fresenius Kabi Recent Developments
11.7 Central Admixture Pharmacy Services Inc
11.7.1 Central Admixture Pharmacy Services Inc Corporation Information
11.7.2 Central Admixture Pharmacy Services Inc Business Overview
11.7.3 Central Admixture Pharmacy Services Inc Bulk-Drug Compounding Product Features and Attributes
11.7.4 Central Admixture Pharmacy Services Inc Bulk-Drug Compounding Revenue and Gross Margin (2020-2025)
11.7.5 Central Admixture Pharmacy Services Inc Recent Developments
11.8 PharMEDium
11.8.1 PharMEDium Corporation Information
11.8.2 PharMEDium Business Overview
11.8.3 PharMEDium Bulk-Drug Compounding Product Features and Attributes
11.8.4 PharMEDium Bulk-Drug Compounding Revenue and Gross Margin (2020-2025)
11.8.5 PharMEDium Recent Developments
11.9 Avella Speciality Pharmacy
11.9.1 Avella Speciality Pharmacy Corporation Information
11.9.2 Avella Speciality Pharmacy Business Overview
11.9.3 Avella Speciality Pharmacy Bulk-Drug Compounding Product Features and Attributes
11.9.4 Avella Speciality Pharmacy Bulk-Drug Compounding Revenue and Gross Margin (2020-2025)
11.9.5 Avella Speciality Pharmacy Recent Developments
11.10 ImprimisRx
11.10.1 ImprimisRx Corporation Information
11.10.2 ImprimisRx Business Overview
11.10.3 ImprimisRx Bulk-Drug Compounding Product Features and Attributes
11.10.4 ImprimisRx Bulk-Drug Compounding Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
11.11 Edge Pharma
11.11.1 Edge Pharma Corporation Information
11.11.2 Edge Pharma Business Overview
11.11.3 Edge Pharma Bulk-Drug Compounding Product Features and Attributes
11.11.4 Edge Pharma Bulk-Drug Compounding Revenue and Gross Margin (2020-2025)
11.11.5 Edge Pharma Recent Developments
11.12 SCA Pharma
11.12.1 SCA Pharma Corporation Information
11.12.2 SCA Pharma Business Overview
11.12.3 SCA Pharma Bulk-Drug Compounding Product Features and Attributes
11.12.4 SCA Pharma Bulk-Drug Compounding Revenue and Gross Margin (2020-2025)
11.12.5 SCA Pharma Recent Developments
11.13 New England Compounding Center
11.13.1 New England Compounding Center Corporation Information
11.13.2 New England Compounding Center Business Overview
11.13.3 New England Compounding Center Bulk-Drug Compounding Product Features and Attributes
11.13.4 New England Compounding Center Bulk-Drug Compounding Revenue and Gross Margin (2020-2025)
11.13.5 New England Compounding Center Recent Developments
11.14 Bellevue Pharmacy
11.14.1 Bellevue Pharmacy Corporation Information
11.14.2 Bellevue Pharmacy Business Overview
11.14.3 Bellevue Pharmacy Bulk-Drug Compounding Product Features and Attributes
11.14.4 Bellevue Pharmacy Bulk-Drug Compounding Revenue and Gross Margin (2020-2025)
11.14.5 Bellevue Pharmacy Recent Developments
11.15 Pharmazone
11.15.1 Pharmazone Corporation Information
11.15.2 Pharmazone Business Overview
11.15.3 Pharmazone Bulk-Drug Compounding Product Features and Attributes
11.15.4 Pharmazone Bulk-Drug Compounding Revenue and Gross Margin (2020-2025)
11.15.5 Pharmazone Recent Developments
12 Bulk-Drug CompoundingIndustry Chain Analysis
12.1 Bulk-Drug Compounding Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Bulk-Drug Compounding Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Bulk-Drug Compounding Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global Bulk-Drug Compounding Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Bulk-Drug Compounding Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Bulk-Drug Compounding Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Bulk-Drug Compounding Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Bulk-Drug Compounding Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global Bulk-Drug Compounding Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global Bulk-Drug Compounding Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global Bulk-Drug Compounding by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Bulk-Drug Compounding as of 2024)
Table 11. Global Bulk-Drug Compounding Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global Bulk-Drug Compounding Companies Headquarters
Table 13. Global Bulk-Drug Compounding Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Bulk-Drug Compounding Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global Bulk-Drug Compounding Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global Bulk-Drug Compounding Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global Bulk-Drug Compounding Revenue by Application (2026-2031) & (US$ Million)
Table 21. Bulk-Drug Compounding High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Bulk-Drug Compounding Growth Accelerators and Market Barriers
Table 25. North America Bulk-Drug Compounding Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe Bulk-Drug Compounding Growth Accelerators and Market Barriers
Table 27. Europe Bulk-Drug Compounding Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific Bulk-Drug Compounding Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Bulk-Drug Compounding Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America Bulk-Drug Compounding Investment Opportunities and Key Challenges
Table 31. Central and South America Bulk-Drug Compounding Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa Bulk-Drug Compounding Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Bulk-Drug Compounding Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. Fogron Corporation Information
Table 35. Fogron Description and Major Businesses
Table 36. Fogron Product Features and Attributes
Table 37. Fogron Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. Fogron Revenue Proportion by Product in 2024
Table 39. Fogron Revenue Proportion by Application in 2024
Table 40. Fogron Revenue Proportion by Geographic Area in 2024
Table 41. Fogron Bulk-Drug Compounding SWOT Analysis
Table 42. Fogron Recent Developments
Table 43. B.Broun Melsungen AG Corporation Information
Table 44. B.Broun Melsungen AG Description and Major Businesses
Table 45. B.Broun Melsungen AG Product Features and Attributes
Table 46. B.Broun Melsungen AG Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. B.Broun Melsungen AG Revenue Proportion by Product in 2024
Table 48. B.Broun Melsungen AG Revenue Proportion by Application in 2024
Table 49. B.Broun Melsungen AG Revenue Proportion by Geographic Area in 2024
Table 50. B.Broun Melsungen AG Bulk-Drug Compounding SWOT Analysis
Table 51. B.Broun Melsungen AG Recent Developments
Table 52. Nephron Pharmaceuticals Corporaiton Corporation Information
Table 53. Nephron Pharmaceuticals Corporaiton Description and Major Businesses
Table 54. Nephron Pharmaceuticals Corporaiton Product Features and Attributes
Table 55. Nephron Pharmaceuticals Corporaiton Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. Nephron Pharmaceuticals Corporaiton Revenue Proportion by Product in 2024
Table 57. Nephron Pharmaceuticals Corporaiton Revenue Proportion by Application in 2024
Table 58. Nephron Pharmaceuticals Corporaiton Revenue Proportion by Geographic Area in 2024
Table 59. Nephron Pharmaceuticals Corporaiton Bulk-Drug Compounding SWOT Analysis
Table 60. Nephron Pharmaceuticals Corporaiton Recent Developments
Table 61. Athenex Pharmaceutical Division Corporation Information
Table 62. Athenex Pharmaceutical Division Description and Major Businesses
Table 63. Athenex Pharmaceutical Division Product Features and Attributes
Table 64. Athenex Pharmaceutical Division Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. Athenex Pharmaceutical Division Revenue Proportion by Product in 2024
Table 66. Athenex Pharmaceutical Division Revenue Proportion by Application in 2024
Table 67. Athenex Pharmaceutical Division Revenue Proportion by Geographic Area in 2024
Table 68. Athenex Pharmaceutical Division Bulk-Drug Compounding SWOT Analysis
Table 69. Athenex Pharmaceutical Division Recent Developments
Table 70. QuVa Pharma Corporation Information
Table 71. QuVa Pharma Description and Major Businesses
Table 72. QuVa Pharma Product Features and Attributes
Table 73. QuVa Pharma Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. QuVa Pharma Revenue Proportion by Product in 2024
Table 75. QuVa Pharma Revenue Proportion by Application in 2024
Table 76. QuVa Pharma Revenue Proportion by Geographic Area in 2024
Table 77. QuVa Pharma Bulk-Drug Compounding SWOT Analysis
Table 78. QuVa Pharma Recent Developments
Table 79. Fresenius Kabi Corporation Information
Table 80. Fresenius Kabi Description and Major Businesses
Table 81. Fresenius Kabi Product Features and Attributes
Table 82. Fresenius Kabi Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. Fresenius Kabi Recent Developments
Table 84. Central Admixture Pharmacy Services Inc Corporation Information
Table 85. Central Admixture Pharmacy Services Inc Description and Major Businesses
Table 86. Central Admixture Pharmacy Services Inc Product Features and Attributes
Table 87. Central Admixture Pharmacy Services Inc Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. Central Admixture Pharmacy Services Inc Recent Developments
Table 89. PharMEDium Corporation Information
Table 90. PharMEDium Description and Major Businesses
Table 91. PharMEDium Product Features and Attributes
Table 92. PharMEDium Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. PharMEDium Recent Developments
Table 94. Avella Speciality Pharmacy Corporation Information
Table 95. Avella Speciality Pharmacy Description and Major Businesses
Table 96. Avella Speciality Pharmacy Product Features and Attributes
Table 97. Avella Speciality Pharmacy Revenue (US$ Million) and Gross Margin (2020-2025)
Table 98. Avella Speciality Pharmacy Recent Developments
Table 99. ImprimisRx Corporation Information
Table 100. ImprimisRx Description and Major Businesses
Table 101. ImprimisRx Product Features and Attributes
Table 102. ImprimisRx Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. ImprimisRx Recent Developments
Table 104. Edge Pharma Corporation Information
Table 105. Edge Pharma Description and Major Businesses
Table 106. Edge Pharma Product Features and Attributes
Table 107. Edge Pharma Revenue (US$ Million) and Gross Margin (2020-2025)
Table 108. Edge Pharma Recent Developments
Table 109. SCA Pharma Corporation Information
Table 110. SCA Pharma Description and Major Businesses
Table 111. SCA Pharma Product Features and Attributes
Table 112. SCA Pharma Revenue (US$ Million) and Gross Margin (2020-2025)
Table 113. SCA Pharma Recent Developments
Table 114. New England Compounding Center Corporation Information
Table 115. New England Compounding Center Description and Major Businesses
Table 116. New England Compounding Center Product Features and Attributes
Table 117. New England Compounding Center Revenue (US$ Million) and Gross Margin (2020-2025)
Table 118. New England Compounding Center Recent Developments
Table 119. Bellevue Pharmacy Corporation Information
Table 120. Bellevue Pharmacy Description and Major Businesses
Table 121. Bellevue Pharmacy Product Features and Attributes
Table 122. Bellevue Pharmacy Revenue (US$ Million) and Gross Margin (2020-2025)
Table 123. Bellevue Pharmacy Recent Developments
Table 124. Pharmazone Corporation Information
Table 125. Pharmazone Description and Major Businesses
Table 126. Pharmazone Product Features and Attributes
Table 127. Pharmazone Revenue (US$ Million) and Gross Margin (2020-2025)
Table 128. Pharmazone Recent Developments
Table 129. Raw Materials Key Suppliers
Table 130. Distributors List
Table 131. Market Trends and Market Evolution
Table 132. Market Drivers and Opportunities
Table 133. Market Challenges, Risks, and Restraints
Table 134. Research Programs/Design for This Report
Table 135. Key Data Information from Secondary Sources
Table 136. Key Data Information from Primary Sources
List of Figures
Figure 1. Bulk-Drug Compounding Product Picture
Figure 2. Global Bulk-Drug Compounding Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Sterile Compounding Product Picture
Figure 4. Non-sterile Compounding Product Picture
Figure 5. Global Bulk-Drug Compounding Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 6. Prescription Drugs
Figure 7. Over-the-Counter Drugs
Figure 8. Bulk-Drug Compounding Report Years Considered
Figure 9. Global Bulk-Drug Compounding Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 10. Global Bulk-Drug Compounding Revenue (2020-2031) & (US$ Million)
Figure 11. Global Bulk-Drug Compounding Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 12. Global Bulk-Drug Compounding Revenue Market Share by Region (2020-2031)
Figure 13. Global Bulk-Drug Compounding Revenue Market Share Ranking (2024)
Figure 14. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 15. Sterile Compounding Revenue Market Share by Player in 2024
Figure 16. Non-sterile Compounding Revenue Market Share by Player in 2024
Figure 17. Global Bulk-Drug Compounding Revenue Market Share by Type (2020-2031)
Figure 18. Global Bulk-Drug Compounding Revenue Market Share by Application (2020-2031)
Figure 19. North America Bulk-Drug Compounding Revenue YoY (2020-2031) & (US$ Million)
Figure 20. North America Top 5 Players Bulk-Drug Compounding Revenue (US$ Million) in 2024
Figure 21. North America Bulk-Drug Compounding Revenue (US$ Million) by Type (2020 - 2031)
Figure 22. North America Bulk-Drug Compounding Revenue (US$ Million) by Application (2020-2031)
Figure 23. US Bulk-Drug Compounding Revenue (2020-2031) & (US$ Million)
Figure 24. Canada Bulk-Drug Compounding Revenue (2020-2031) & (US$ Million)
Figure 25. Mexico Bulk-Drug Compounding Revenue (2020-2031) & (US$ Million)
Figure 26. Europe Bulk-Drug Compounding Revenue YoY (2020-2031) & (US$ Million)
Figure 27. Europe Top 5 Players Bulk-Drug Compounding Revenue (US$ Million) in 2024
Figure 28. Europe Bulk-Drug Compounding Revenue (US$ Million) by Type (2020-2031)
Figure 29. Europe Bulk-Drug Compounding Revenue (US$ Million) by Application (2020-2031)
Figure 30. Germany Bulk-Drug Compounding Revenue (2020-2031) & (US$ Million)
Figure 31. France Bulk-Drug Compounding Revenue (2020-2031) & (US$ Million)
Figure 32. U.K. Bulk-Drug Compounding Revenue (2020-2031) & (US$ Million)
Figure 33. Italy Bulk-Drug Compounding Revenue (2020-2031) & (US$ Million)
Figure 34. Russia Bulk-Drug Compounding Revenue (2020-2031) & (US$ Million)
Figure 35. Asia-Pacific Bulk-Drug Compounding Revenue YoY (2020-2031) & (US$ Million)
Figure 36. Asia-Pacific Top 8 Players Bulk-Drug Compounding Revenue (US$ Million) in 2024
Figure 37. Asia-Pacific Bulk-Drug Compounding Revenue (US$ Million) by Type (2020-2031)
Figure 38. Asia-Pacific Bulk-Drug Compounding Revenue (US$ Million) by Application (2020-2031)
Figure 39. Indonesia Bulk-Drug Compounding Revenue (2020-2031) & (US$ Million)
Figure 40. Japan Bulk-Drug Compounding Revenue (2020-2031) & (US$ Million)
Figure 41. South Korea Bulk-Drug Compounding Revenue (2020-2031) & (US$ Million)
Figure 42. Australia Bulk-Drug Compounding Revenue (2020-2031) & (US$ Million)
Figure 43. India Bulk-Drug Compounding Revenue (2020-2031) & (US$ Million)
Figure 44. Indonesia Bulk-Drug Compounding Revenue (2020-2031) & (US$ Million)
Figure 45. Vietnam Bulk-Drug Compounding Revenue (2020-2031) & (US$ Million)
Figure 46. Malaysia Bulk-Drug Compounding Revenue (2020-2031) & (US$ Million)
Figure 47. Philippines Bulk-Drug Compounding Revenue (2020-2031) & (US$ Million)
Figure 48. Singapore Bulk-Drug Compounding Revenue (2020-2031) & (US$ Million)
Figure 49. Central and South America Bulk-Drug Compounding Revenue YoY (2020-2031) & (US$ Million)
Figure 50. Central and South America Top 5 Players Bulk-Drug Compounding Revenue (US$ Million) in 2024
Figure 51. Central and South America Bulk-Drug Compounding Revenue (US$ Million) by Type (2020-2031)
Figure 52. Central and South America Bulk-Drug Compounding Revenue (US$ Million) by Application (2020-2031)
Figure 53. Brazil Bulk-Drug Compounding Revenue (2020-2025) & (US$ Million)
Figure 54. Argentina Bulk-Drug Compounding Revenue (2020-2025) & (US$ Million)
Figure 55. Middle East and Africa Bulk-Drug Compounding Revenue YoY (2020-2031) & (US$ Million)
Figure 56. Middle East and Africa Top 5 Players Bulk-Drug Compounding Revenue (US$ Million) in 2024
Figure 57. South America Bulk-Drug Compounding Revenue (US$ Million) by Type (2020-2031)
Figure 58. Middle East and Africa Bulk-Drug Compounding Revenue (US$ Million) by Application (2020-2031)
Figure 59. GCC Countries Bulk-Drug Compounding Revenue (2020-2025) & (US$ Million)
Figure 60. Israel Bulk-Drug Compounding Revenue (2020-2025) & (US$ Million)
Figure 61. Egypt Bulk-Drug Compounding Revenue (2020-2025) & (US$ Million)
Figure 62. South Africa Bulk-Drug Compounding Revenue (2020-2025) & (US$ Million)
Figure 63. Bulk-Drug Compounding Industry Chain Mapping
Figure 64. Channels of Distribution (Direct Vs Distribution)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed
